gamida cell

Inspired to Cure

Annual General Meeting of Shareholders

September 10, 2020

Disclaimer

This Presentation includes certain projections and forward-looking statements as of the date of this Presentation provided by Gamida Cell Ltd (the "company"). The information in this Presentation is current only as of its date and may have changed since that date. These projections and forward-looking statements include, but are not limited to, those regarding the company's future financial position and results of operations, the company's commercialization, marketing and manufacturing capabilities and strategy, the company's intellectual property position, regulatory matters, market size and opportunity and the company's estimates regarding expenses, future revenues, capital requirements and needs for additional financing. These projections and forward-looking statements are based on the beliefs of the company's management as well as assumptions made and information currently available to the company. Such statements reflect the current views of the company with respect to future events and are subject to business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about the company and its subsidiaries and investments, including, among other things, the development of its business, trends in the industry, the legal and regulatory framework for the industry and future expenditures. In light of these risks, uncertainties, contingencies and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in this presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the presentation. The actual results may vary from the anticipated results and the variations may be material.

We are pioneering new, potentially curative advanced cell therapies.

Recent Accomplishments

Omidubicel, an advanced cell therapy for bone marrow transplant

- ✓ Reported positive data from Phase 3 study
- ✓ Initiated expanded access program
- ✓ Reported data from observational study conducted in collaboration with Center for International Blood and Marrow Transplant Research® (CIBMTR®)
- ✓ Completed tech transfer to Lonza Netherlands, our contract manufacturer, and completed construction of our own commercial manufacturing facility

GDA-201, a natural killer (NK) cell therapy

- ✓ Advanced activities to support IND submission of GDA-201

Corporate Developments

- ✓ Completed follow-on equity offering with gross proceeds of ~$69M
- ✓ Added new leadership to board of directors and management team

Omidubicel

A potentially curative treatment for patients in need of a bone marrow transplant

gamida cell

Omidubicel May Address a Significant Patient Population in the U.S.



MUD: Matched unrelated donor; **haplo**: Haploidentical; **MRD**: Matched related donor

Phase 3 Global, Randomized Study Conducted at Over 50 Sites



Primary endpoint: Time to neutrophil engraftment

Secondary endpoints: Platelet engraftment, infections, hospitalizations

Additional endpoints: Acute GvHD, chronic GvHD, adverse events, non-relapse mortality, disease-free survival

Clinicaltrials.gov identifier NCT01221857.

Phase 3 Primary Endpoint
Omidubicel Significantly Reduced Time to Engraftment

Intent-to-treat	Median Time to Neutrophil Engraftment (Days)	95% CI	
Omidubicel (N = 62)	12.0	(10.0, 15.0)	p<0.001
Comparator (N = 63)	22.0	(19.0, 25.0)	

- Demographics and baseline characteristics were well-balanced in the two arms
- Omidubicel was generally well tolerated

Engraftment is a key milestone in recovery
Rapid engraftment is associated with fewer infections and shorter hospitalizations[1]

Anand et al. *BBMT* 23:1151-7, 2017.

Phase 1/2 Omidubicel Study Demonstrated That Rapid Engraftment Is Associated with Fewer Infections and Shorter Hospitalizations

Infection



Total Infections

Bacterial Infections

Hospitalization



~20 fewer days in hospital with omidubicel

Anand et al. *BBMT* 23:1151-7, 2017.

gamida cell

Phase 3 Data

Cumulative Incidence of Neutrophil Engraftment in As-Treated Population



*Comparator is standard cord blood.
AT: As treated population (received transplantation with omidubicel or comparator per protocol).

gamida cell

Omidubicel Single-Arm Study Initiated

- Expanded access program being conducted through a single-arm, open-label study provides opportunities to:
  - Provide access to treatment prior to approval
  - Enable continued engagement with transplant centers
  - Collect additional clinical data
  - Support BLA filing
- First three sites activated in the U.S.
  - Additional sites expected to open in the coming months

Overall Survival Is Increased in Patients with Younger Donors

Methodology

- Ongoing collaboration with CIBMTR to explore outcomes contemporaneous to the Phase 3 study of omidubicel
- Patients underwent myeloablative conditioning and HSCT for hematologic malignancies
- HSCT with three graft types: matched unrelated, mismatched unrelated, and haploidentical donors
- Median age of all donors: 30 years



Stem cells, the starting point for omidubicel, are the "youngest" cell type used in allogeneic bone marrow transplant

Galamidi E, Joyce A, Simantov R. Impact of Donor Age on HSCT Outcomes. Cord Blood Connect. Sept. 2020.

gamida cell

Manufacturing Readiness On Track to Support Potential 2H21 Launch

- Anticipate initial commercial supply to be produced by Lonza
  - ✓ Technology transfer completed
- Scalable, Gamida Cell-owned manufacturing facility can further enable reliable, consistent supply
  - ✓ Construction complete
  - – Validation expected to be complete by year-end 2020



Photos of Gamida Cell-owned facility.

Preparing for a Successful Omidubicel Launch



Omidubicel Key Takeaways

- Potential to be first FDA-approved bone marrow transplant graft
- Compelling clinical profile to date
  - Unprecedented time to neutrophil engraftment
  - Generally well-tolerated
  - Reduced hospitalization time and decreased risk of infection
- Initiation of rolling BLA submission anticipated in 4Q20
- Pre-commercial activities underway for potential 2H21 launch

After receiving a bone marrow transplant with omidubicel in 2011, Stacey remains cancer free

This is one patient and results may not be indicative. Omidubicel is investigational and safety and efficacy have not been established by any agency.

GDA-201

Harnessing Innate Immunity Using Natural Killer (NK) Cells to Treat Cancer

gamida cell

Putting NK Cells to Work Using Our NAM Technology Platform

Benefits of NK Cells

- Natural killer (NK) cells infusion is a promising immune therapy for cancer
  - No HLA matching required
  - Synergy with antibodies
  - Potential for off-the-shelf therapy
- Expansion is necessary to obtain clinically meaningful doses with retained cell function

GDA-201: NK Cells + Tumor-specific Antibodies



Phase 1 Study of GDA-201 in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma



- **Primary endpoint:** Maximum tolerated dose of GDA-201 (3 doses evaluated)
- **Secondary endpoints:** Overall response, toxicity

ClinicalTrials.gov Identifier NCT03019666.

Phase 1 Data: GDA-201 Is Highly Active in Non-Hodgkin Lymphoma





FL: Follicular lymphoma
DLBCL: diffuse large B cell lymphoma

Bachanova et al., based on EBMT 2020 abstract.

GDA-201 Phase 1 Study: Key Takeaways



Data support Phase 1/2 multi-center, multi-dose study in NHL

Bachanova et al. EBMT 2020 abstract. Bachanova et al. ASH 2019.

Financial Snapshot

- June 30th cash position: $88.6 million*
- Cash supports capital needs into 2H21*
- Approximately 90 employees

*Includes cash, cash equivalents, marketed securities and short-term deposits. Cash runway guidance is based on our current operational plans, including the assumption that we will continue to advance both our commercial readiness and all our clinical programs and excludes any additional funding that may be received or business development activities that may be undertaken.

Expected 2020-2021 Milestones

Omidubicel

- ✓ Report topline data from the Phase 3 study in 2Q20
- ❑ Present data from the Phase 3 study at a medical meeting in 4Q20
- ❑ Initiate rolling BLA submission in 4Q20
- ❑ Report additional data from the Phase 1/2 study in patients with severe aplastic anemia in 4Q20
- ❑ Launch omidubicel in 2021*

GDA-201

- ✓ Present additional data from the Phase 1 study in 1H20**
- ❑ Submit IND in 1H21
- ❑ Initiate a Phase 1/2 clinical study in NHL in 2021

*Pending BLA submission, acceptance and subsequent FDA approval.
** Data accepted for EBMT2020, which was to be held in March and then postponed due to COVID-19.

gamida cell

Inspired to Cure

Annual General Meeting of Shareholders

September 10, 2020